Current and future developments in the use of temozolomide for the treatment of brain tumours

This publication has 46 references indexed in Scilit:

• Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
  British Journal of Cancer, 1999
• DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
  Journal of Clinical Oncology, 1998
• Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration
  Cancer Chemotherapy and Pharmacology, 1998
• Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials
  Published by Elsevier ,1997
• Intracellular localization and intercellular heterogeneity of the human DNA repair protein O 6 -methylguanine-DNA methyltransferase
  Cancer Chemotherapy and Pharmacology, 1996
• Antitumor Imidazotetrazines. 32.1 Synthesis of Novel Imidazotetrazinones and Related Bicyclic Heterocycles To Probe the Mode of Action of the Antitumor Drug Temozolomide
  Journal of Medicinal Chemistry, 1995
• From triazines and triazenes to temozolomide
  European Journal Of Cancer, 1993
• Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
  British Journal of Cancer, 1992
• Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity
  Cancer Chemotherapy and Pharmacology, 1990
• Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agent
  Journal of Medicinal Chemistry, 1984